> 43 Cáncer de ovario avanzado. Tratamiento de primera línea BIBLIOGRAFÍA 1. Madariaga A, Bowering V, Ahrari S, Oza AM, LHeureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020;30(7):903-15. 2. Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oakin A, Wilson MK, et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;Jun(6):2201003;2022. DOI: 10.1200/ JCO.22.01003 3. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCAmutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 1022;22(12):1721-31. 4. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oakin A, et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial. Ann Oncol. 2022;33:S235-S282. 5. González-Martín A, Pothuri B, Vergote I, DePont R, Graybill W, Myrza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-402. 6. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín AJ, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-28. 7. Ray-Coquard IL, LearyA, Pignata S, Cropet C, González-Martín, AJ, Bogner G, et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). Ann Oncol. 2022;33:S808-S869.
RkJQdWJsaXNoZXIy MTQzMjMwMg==